



## Apogee Therapeutics to Participate in Upcoming June Conferences

May 28, 2026

SAN FRANCISCO and BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), today announced that members of management will participate at the following investor conferences.

### **Jefferies Global Healthcare Conference**

Date: Wednesday, June 3, 2026

Fireside Time: 11:40 a.m. ET

### **Goldman Sachs 47<sup>th</sup> Annual Global Healthcare Conference**

Date: Wednesday, June 10, 2026

Fireside Time: 9:20 a.m. ET

A live and archived webcast of the fireside chats will be available via the [News & Events](#) page in the Investors section of the Apogee Therapeutics website.

### **About Apogee**

Apogee Therapeutics is a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest I&I markets, including for the treatment of AD, asthma, EoE, Chronic Obstructive Pulmonary Disease (COPD) and other I&I indications. Apogee's antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Zumilokibart, the company's most advanced program, is being initially developed for the treatment of AD, which is the largest and one of the least penetrated I&I markets, as well as asthma and EoE. With four validated targets in its portfolio, Apogee is seeking to achieve best-in-class efficacy and dosing through monotherapies and combinations of its novel antibodies. Based on a broad pipeline and depth of expertise, the company believes it can deliver value and meaningful benefit to patients underserved by today's standard of care. For more information, please visit <https://apogeetherapeutics.com>.

### **Investor Contact:**

Noel Kurdi

VP, Investor Relations

Apogee Therapeutics, Inc.

[noel.kurdi@apogeetherapeutics.com](mailto:noel.kurdi@apogeetherapeutics.com)

### **Media Contact:**

Dan Budwick

1AB

[dan@1abmedia.com](mailto:dan@1abmedia.com)